123 related articles for article (PubMed ID: 12877889)
1. Transfusion-related acute lung injury (TRALI) following platelet transfusion in a patient receiving high-dose interleukin-2 for treatment of metastatic renal cell carcinoma.
Medeiros BC; Kogel KE; Kane MA
Transfus Apher Sci; 2003 Aug; 29(1):25-7. PubMed ID: 12877889
[TBL] [Abstract][Full Text] [Related]
2. Metastatic renal cell carcinoma: systemic treatment.
Abi-Aad AS; deKernion JB
Acta Urol Belg; 1996 May; 64(2):3-8. PubMed ID: 8701805
[No Abstract] [Full Text] [Related]
3. Patient-specific transfusion-related acute lung injury.
Muniz M; Sheldon S; Schuller RM; Young NS; Klein HG; Leitman SF; Stroncek DF
Vox Sang; 2008 Jan; 94(1):70-3. PubMed ID: 18171330
[TBL] [Abstract][Full Text] [Related]
4. High-dose interleukin-2 immunotherapy is safe for patients with metastatic renal cell carcinoma on dialysis.
Brusky JP; Gailani F; Pathak A; Patel H; Aboseif S
BJU Int; 2006 Feb; 97(2):279-80. PubMed ID: 16430629
[TBL] [Abstract][Full Text] [Related]
5. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials.
Leibovich BC; Han KR; Bui MH; Pantuck AJ; Dorey FJ; Figlin RA; Belldegrun A
Cancer; 2003 Dec; 98(12):2566-75. PubMed ID: 14669275
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-2 based immunotherapy in patients with metastatic renal cell carcinoma.
Donskov F
Dan Med Bull; 2007 Nov; 54(4):249-65. PubMed ID: 18208677
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of IL-2 immunotherapy in metastatic renal cell carcinoma in relation to the psychic profile as evaluated using the Rorschach test.
Messina G; Lissoni P; Bartolacelli E; Fumagalli L; Brivio F; Colombo E; Gardani GS
Anticancer Res; 2007; 27(4C):2985-8. PubMed ID: 17695482
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy of renal cell carcinoma with granulocyte macrophage colony stimulating factor and very low dose interleukin-2.
Correale P; Marsili S; Sabatino M; Montagnani F; Giorgi G; Francini G
Oncol Rep; 2005 Apr; 13(4):751-6. PubMed ID: 15756453
[TBL] [Abstract][Full Text] [Related]
10. Ipsilateral right testicular metastasis from renal cell carcinoma in a responder patient to interleukine-2 treatment.
Camerini A; Tartarelli G; Martini L; Donati S; Puccinelli P; Amoroso D
Int J Urol; 2007 Mar; 14(3):259-60. PubMed ID: 17430270
[TBL] [Abstract][Full Text] [Related]
11. High-dose interleukin-2 in metastatic renal cell carcinoma.
Fernández-Rodríguez R; de Argumedo GL; Mañé JM; Muñoz A; Ferreiro J; Fuente N; López-Vivanco G
J Clin Oncol; 2005 Sep; 23(27):6797-8; author reply 6798-9. PubMed ID: 16170190
[No Abstract] [Full Text] [Related]
12. Successful treatment of a patient on adrenal steroid replacement therapy with high-dose bolus interleukin-2 for metastatic renal cell carcinoma.
Deshpande H; Dutcher JP; Novik Y; Oleksowicz L
Cancer J Sci Am; 1999; 5(1):52-3. PubMed ID: 10188062
[No Abstract] [Full Text] [Related]
13. Increased disease activity in a patient with sarcoidosis after high dose interleukin 2 treatment for metastatic renal cancer.
Logan TF; Bensadoun ES
Thorax; 2005 Jul; 60(7):610-1. PubMed ID: 15994271
[TBL] [Abstract][Full Text] [Related]
14. How much residual plasma may cause TRALI?
Win N; Chapman CE; Bowles KM; Green A; Bradley S; Edmondson D; Wallis JP
Transfus Med; 2008 Oct; 18(5):276-80. PubMed ID: 18937733
[TBL] [Abstract][Full Text] [Related]
15. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy.
Casamassima A; Picciariello M; Quaranta M; Berardino R; Ranieri C; Paradiso A; Lorusso V; Guida M
J Urol; 2005 Jan; 173(1):52-5. PubMed ID: 15592024
[TBL] [Abstract][Full Text] [Related]
16. Fas ligand expression in metastatic renal cell carcinoma during interleukin-2 based immunotherapy: no in vivo effect of Fas ligand tumor counterattack.
Donskov F; von der Maase H; Marcussen N; Hamilton-Dutoit S; Madsen HH; Jensen JJ; Hokland M
Clin Cancer Res; 2004 Dec; 10(23):7911-6. PubMed ID: 15585624
[TBL] [Abstract][Full Text] [Related]
17. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.
Varker KA; Kondadasula SV; Go MR; Lesinski GB; Ghosh-Berkebile R; Lehman A; Monk JP; Olencki T; Kendra K; Carson WE
Clin Cancer Res; 2006 Oct; 12(19):5850-8. PubMed ID: 17020993
[TBL] [Abstract][Full Text] [Related]
18. Recurrence of pemphigus vulgaris associated with interleukin 2 therapy.
Prussick R; Plott RT; Stanley JR
Arch Dermatol; 1994 Jul; 130(7):890-3. PubMed ID: 7794299
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for metastatic renal cell carcinoma.
McDermott DF; Rini BI
BJU Int; 2007 May; 99(5 Pt B):1282-8. PubMed ID: 17441925
[No Abstract] [Full Text] [Related]
20. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer.
Parton M; Gore M; Eisen T
J Clin Oncol; 2006 Dec; 24(35):5584-92. PubMed ID: 17158544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]